SCRM,Screaming Eagle Acquisition Corp. | Financials

Update: Corus Entertainment Falls 20% as it Meets Fiscal Q2 Forecasts But Sees Drop in FQ3 TV Advertising Revenues

Apr 12, 2024

12:00 PM EDT, 04/12/2024 (MT Newswires) -- Corus Entertainment (CJR-B.TO) on Friday said its fiscal second-quarter loss narrowed while it warned it expects lower advertising revenue for its current quarter. The broadcaster reported a fiscal second-quarter adjusted loss of C$5.94 million, or C$0.03 per share, in the quarter ended Feb.29, narrowing from a loss of C$13.88 million, or C$0.07 per...

JPMorgan's Net Interest Income Outlook Is 'Moderate Disappointment' Amid 'Solid' Q1 Results, HSBC Says

Apr 12, 2024

12:02 PM EDT, 04/12/2024 (MT Newswires) -- JPMorgan Chase's ( JPM ) net interest income outlook this year probably was assessed as a moderate disappointment amid solid Q1 results on a decrease in loan losses, higher non-interest income and lower expenses, HSBC Global Research said Friday in a note. JPMorgan ( JPM ) kept its 2024 net interest income outlook...

European Equities Close Mixed in Friday Trading; German Inflation Slows, UK GDP Rises

Apr 12, 2024

12:08 PM EDT, 04/12/2024 (MT Newswires) -- European stock markets closed mixed in Friday trading as the Stoxx Europe 600 was up 0.14%, the Swiss Market Index lost 0.75%, France's CAC was off 0.16%, the FTSE in London rose 0.91%, and Germany's DAX was down 0.13%. In Germany, the consumer price index was 2.2% in March, down from 2.5% in...

Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies

Apr 12, 2024

Friday, PaxMedica Inc ( PXMD ) completed the execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin. This achievement is an essential milestone in enabling a New Drug Application submission to the FDA, which is currently planned for Q4 2024, and the potential commercial availability in the U.S. of the first and only form of suramin for Stage...